Adults aged 18 to 49 years at increased risk for RSV-associated lower respiratory tract disease are now eligible for the ...

The approval represents a win in what’s been a difficult regulatory environment of late for vaccine makers, and could boost ...

GSK’s RSV vaccine, AREXVY, approved in US for expanded age indication in adults aged 18–49 years at increased risk ...

Arexvy will now compete for market share with Pfizer’s Abrysvo and Moderna’s mRESVIA in this expanded, high-risk adult ...

Arexvy (respiratory syncytial virus vaccine, adjuvanted) is a vaccine that’s used to prevent respiratory syncytial virus (RSV) infection. The vaccine is given as a single injection into a muscle by a ...

GSK plc GSK announced that the FDA approved the expanded use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 18 to 49 years who are at a higher risk of ...

Arexvy (respiratory syncytial virus vaccine, adjuvanted) is a brand-name intramuscular injection that’s prescribed to help prevent a lung infection that’s caused by RSV infection in adults. The cost ...

*The vaccine efficacy is estimated using a Poisson model adjusted by age, region and season. A similar pattern of vaccine efficacy over two seasons was also observed in adults with underlying ...

FDA now permits Arexvy for adults 18–49 with elevated RSV risk from conditions such as chronic cardiopulmonary or renal ...

Arexvy, a respiratory syncytial virus (RSV) vaccine, is a brand-name intramuscular injection. It’s prescribed to help prevent lower respiratory infections from RSV. Arexvy has no known interactions ...

Over 13 million adults aged 50-59 at increased risk in the US can potentially benefit from RSV immunization 1 RSV causes an estimated 42,000 hospitalizations* each year in adults aged 50-64 years old ...

The "AREXVY Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering. The pharmaceutical landscape for Respiratory Syncytial Virus (RSV) is poised ...